Granules India informs about press release

04 Aug 2023 Evaluate

Granules India has that it enclosed press release today titled ‘Granules Pharmaceuticals, Inc. Successfully Completes USFDA Postmarketing Adverse Drug Experience (PADE) Inspection with Zero Observations’.

The above information is a part of company’s filings submitted to BSE.

Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.